Ciprofloxacin Intravenous Dosing
For adults, administer ciprofloxacin IV 400 mg every 12 hours for most infections, or 400 mg every 8 hours for severe/complicated infections, nosocomial pneumonia, and empirical therapy in febrile neutropenia, with dose adjustments required when creatinine clearance falls below 30 mL/min. 1
Adult Dosing by Indication
The FDA-approved dosing varies by infection severity and type 1:
Standard Dosing (Normal Renal Function)
Mild to moderate infections: 400 mg IV every 12 hours
- Lower respiratory tract infections: 7-14 days
- Skin/skin structure infections: 7-14 days
- Acute sinusitis: 10 days
- Chronic bacterial prostatitis: 28 days
- Complicated intra-abdominal (with metronidazole): 7-14 days
Severe/complicated infections: 400 mg IV every 8 hours
- Lower respiratory tract infections: 7-14 days
- Nosocomial pneumonia: 10-14 days
- Skin/skin structure infections: 7-14 days
- Bone and joint infections: ≥4-6 weeks
- Empirical therapy in febrile neutropenia (with piperacillin): 7-14 days
Inhalational anthrax (post-exposure): 400 mg IV every 12 hours for 60 days
Renal Impairment Adjustments
The dosing algorithm based on creatinine clearance is straightforward 1:
- CrCl >30 mL/min: Use standard dosing (no adjustment needed)
- CrCl 5-29 mL/min: 200-400 mg every 18-24 hours
Research supports that prolonging the dosing interval is preferable to dose reduction in renal failure, as this maintains peak concentrations necessary for bacterial eradication while accounting for reduced clearance 2. The pharmacokinetic data demonstrate a positive correlation between ciprofloxacin clearance and creatinine clearance (r² = 0.78), with renal clearance accounting for approximately 40-50% of total drug elimination 3, 4.
Critical Illness Considerations
In septic shock or critically ill patients with augmented renal clearance, standard dosing may be insufficient. Recent evidence suggests that patients with eGFR >100 mL/min and infections caused by pathogens with MIC ≥0.5 mg/L may require doses up to 600 mg every 8 hours to achieve adequate AUC/MIC ratios >125 5, 6. However, for pathogens with MIC ≤0.25 mg/L, standard dosing of 400 mg every 8 hours achieves >95% probability of target attainment in patients with normal or reduced renal function 6.
Pediatric Dosing
For children, administer ciprofloxacin IV 20-30 mg/kg/day divided every 8-12 hours, with a maximum single dose of 400 mg 7.
The American Academy of Pediatrics guideline specifies 7:
- Dose range: 20-30 mg/kg/day IV
- Frequency: Divided every 8-12 hours
- Maximum single dose: 400 mg per dose
For inhalational anthrax post-exposure in pediatric patients, the dosing is 10 mg/kg IV every 12 hours (maximum 400 mg per dose) for 60 days 1.
Important Pediatric Considerations
Ciprofloxacin use in children should be reserved for infections where no alternative exists due to arthropathy concerns documented in juvenile animals 7, 1. The guideline emphasizes that fluoroquinolones are effective for specific pediatric infections including complicated UTIs caused by multidrug-resistant organisms, gastrointestinal infections from Salmonella/Shigella species, and inhalational anthrax 7.
Administration Guidelines
- Infusion time: Administer over 60 minutes to minimize venous irritation and hypotensive effects 1
- Conversion to oral: May switch to oral ciprofloxacin when clinically appropriate, using equivalent AUC dosing (400 mg IV q12h = 500 mg PO q12h; 400 mg IV q8h = 750 mg PO q12h) 1
Common Pitfalls
Failing to adjust for renal impairment: Even though ciprofloxacin has alternative elimination pathways (hepatic, biliary), dose adjustment is still necessary when CrCl <30 mL/min 1
Underdosing in augmented renal clearance: Critically ill patients with high creatinine clearance may require higher doses than standard recommendations 5, 6
Using dose reduction instead of interval extension in renal failure: Prolonging the interval maintains peak concentrations needed for concentration-dependent killing while accounting for reduced clearance 2
Inadequate dosing for less susceptible organisms: For empirical treatment of Pseudomonas aeruginosa, standard dosing may only achieve 68% fractional target attainment; directed therapy may require 600 mg every 8 hours 6